Royal Bank Of Canada Reaffirms HCA Healthcare As 'Outperform'

HCA Healthcare (NYSE:HCA) has had its 'outperform' rating reaffirmed by investment analysts at Royal Bank Of Canada in a research note issued to investors on Monday.

The analysts have a target price of $435.00 on the stock, which implies a potential upside of 12.46% from the company's previous close.

This is not the first time HCA Healthcare has received a positive rating from Royal Bank Of Canada; in July, Raymond James Financial set a target price of $528.00 on shares of the company.